| Literature DB >> 32560359 |
Armando Cevenini1,2, Christian Celia3,4, Stefania Orrù2,5,6, Daniela Sarnataro1, Maddalena Raia2, Valentina Mollo7, Marcello Locatelli3, Esther Imperlini6, Nicoletta Peluso1,2, Rosa Peltrini1,2,8, Enrica De Rosa4, Alessandro Parodi6,9, Luigi Del Vecchio1,2, Luisa Di Marzio3, Massimo Fresta10, Paolo Antonio Netti7,11, Haifa Shen4,12, Xuewu Liu4, Ennio Tasciotti2,13,14, Francesco Salvatore1,2.
Abstract
Mesoporous silicon microparticles (MSMPs) can incorporate drug-carrying nanoparticles (NPs) into their pores. An NP-loaded MSMP is a multistage vector (MSV) that forms a Matryoshka-like structure that protects the therapeutic cargo from degradation and prevents its dilution in the circulation during delivery to tumor cells. We developed an MSV constituted by 1 µm discoidal MSMPs embedded with PEGylated liposomes containing oxaliplatin (oxa) which is a therapeutic agent for colorectal cancer (CRC). To obtain extra-small liposomes able to fit the 60 nm pores of MSMP, we tested several liposomal formulations, and identified two optimal compositions, with a prevalence of the rigid lipid 1,2-distearoyl-sn-glycero-3-phosphocholine and of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]. To improve the MSV assembly, we optimized the liposome-loading inside the MSMP and achieved a five-fold increase of the payload using an innovative lyophilization approach. This procedure also increased the load and limited dimensional changes of the liposomes released from the MSV in vitro. Lastly, we found that the cytotoxic efficacy of oxa-loaded liposomes and-oxa-liposome-MSV in CRC cell culture was similar to that of free oxa. This study increases knowledge about extra-small liposomes and their loading into porous materials and provides useful hints about alternative strategies for designing drug-encapsulating NPs.Entities:
Keywords: colon cancer; liposome; mesoporous silicon microparticle; multistage vector; nanoparticle; oxaliplatin
Year: 2020 PMID: 32560359 DOI: 10.3390/pharmaceutics12060559
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321